TAS-102, a novel antitumor agent: a review of the mechanism of action.
about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewThe dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C)SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.TAS-102 for the treatment of metastatic colorectal cancer.Oral versus intravenous fluoropyrimidines for colorectal cancer.A novel antimetabolite: TAS-102 for metastatic colorectal cancer.Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer.Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report.Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments.Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer.TAS-102 and the quest for predictive biomarkers.Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancerEfficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
P2860
Q26740067-36795F0A-3784-4F94-B477-828B9E2CE8B6Q33779523-EEDCF641-21BC-46F8-911C-539CFE4A9E82Q33878949-C0570456-2026-435C-AC68-40D034F8C8FEQ37703201-7169C0B2-9D36-463E-B9B0-127B9CB6FBB8Q38618169-8B41B789-4206-4388-9B61-6AEF39CA8CF0Q38650502-69CD63D8-8099-4FA3-9410-BDDE6F6E932DQ38671965-400D2E7B-70B5-44FB-9E9B-C783940B5420Q38697671-A2AB884C-70E2-4071-8422-6C273A759CB1Q38705982-856B0B52-2198-4FDD-9F13-DF9BDC5BCAF9Q38827897-20CE0F96-D3F1-42C5-B436-0E61730A0D97Q38857704-065A4A66-5BCA-4790-82D8-4875825A214BQ40081348-5DB18678-9A5B-49BC-80A9-8265A3F39494Q42367389-D1C42062-C292-4037-B7E4-DD7133AD80D5Q48580029-76FAB486-17C1-4842-9226-D373001A1173Q50128950-E34F527F-AD43-41FB-8A91-070C76D76304Q51743257-92B8ED42-615E-44E0-8C71-03083AB3B4AFQ52599217-62AA45C7-B69D-4909-ACA4-AFD9B2CF9BA4Q55347051-5728856B-8B10-4250-83E5-F197477B491DQ55389129-02EB285A-D707-4DF9-AF81-5690E048E1E5Q57788662-29096E05-FF1D-44E8-A148-5F599BD65F03Q58698641-378F4179-E157-44A0-9A72-F4E702299ACE
P2860
TAS-102, a novel antitumor agent: a review of the mechanism of action.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
TAS-102, a novel antitumor agent: a review of the mechanism of action.
@en
type
label
TAS-102, a novel antitumor agent: a review of the mechanism of action.
@en
prefLabel
TAS-102, a novel antitumor agent: a review of the mechanism of action.
@en
P2860
P1476
TAS-102, a novel antitumor agent: a review of the mechanism of action.
@en
P2093
Fotios Loupakis
Sebastian Stintzing
P2860
P304
P356
10.1016/J.CTRV.2015.06.001
P577
2015-06-06T00:00:00Z